Ignite Creation Date:
2025-12-25 @ 2:42 AM
Ignite Modification Date:
2026-03-15 @ 10:08 PM
Study NCT ID:
NCT01127633
Status:
TERMINATED
Last Update Posted:
2019-10-08
First Post:
2010-05-19
Is Gene Therapy:
True
Has Adverse Events:
True
Brief Title:
Continued Safety Monitoring of Solanezumab (LY2062430) in Alzheimer's Disease
Sponsor:
Eli Lilly and Company
Organization:
Study Overview
Official Title:
Continued Efficacy and Safety Monitoring of Solanezumab, an Anti-Amyloid β Antibody in Patients With Alzheimer's Disease
Status:
TERMINATED
Status Verified Date:
2019-09
Last Known Status:
None
Delayed Posting:
No
If Stopped, Why?:
Solanezumab did not meet the primary endpoint in study H8A-MC-LZAX.
Has Expanded Access:
False
If Expanded Access, NCT#:
N/A
Has Expanded Access, NCT# Status:
N/A
Acronym:
EXPEDITION EXT
Brief Summary:
This study is an open-label extension study in Alzheimer's patients who have completed participation in either solanezumab Clinical Trial H8A-MC-LZAM (NCT00905372) or H8A-MC-LZAN (NCT00904683).
Detailed Description:
None
Study Oversight
Has Oversight DMC:
True
Is a FDA Regulated Drug?:
None
Is a FDA Regulated Device?:
None
Is an Unapproved Device?:
None
Is a PPSD?:
None
Is a US Export?:
None
Is an FDA AA801 Violation?:
Secondary ID Infos
| Secondary ID | Type | Domain | Link | View |
|---|---|---|---|---|
| H8A-MC-LZAO | OTHER | Eli Lilly and Company | View |